REPLIGEN CORP (RGEN) Form 8-K — Oct 27, 2026
Repligen reported record Q3 2026 revenue of $209.3 million, up 11% as reported and 12.5% organically, and raised its full-year 2026 revenue guidance to $844-$852 million representing 14.5%-15.5% reported growth. GAAP results showed a Q3 loss of $0.68 per diluted share on a $29.5 million operating loss, driven primarily by a $41.2 million intangible asset impairment charge; adjusted EPS rose to $0.53 from $0.46 a year ago. The company closed its acquisition of BioLife Solutions on October 6, 2026, strengthening its cell therapy consumables platform, and opened a new Training & Innovation Center in Seoul.
Key figures
- Eps
- -0.68
- Revenue
- 209300000
- Guidance
- FY2026 revenue $844M-$852M (14.5%-15.5% reported growth, 12%-13% organic); adjusted operating income $135M-$139M; adjusted diluted EPS $2.05-$2.09
- Total Debt
- 555596000
- Revenue Yoy
- 11% reported / 12.5% organic
- Total Assets
- 2926408000
- Cash Position
- 863000000
- Adjusted eps q3
- 0.53
- Shares outstanding
- 56692755
- Intangible impairment
- 41242000
- Adjusted eps prior year
- 0.46
- Adjusted ebitda margin q3
- 20.9%
- Loss on sale of business ytd
- 13694000
- Adjusted income from operations q3
- 33288000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.